Postpartum Mastitis in the Breastfeeding Women and Antimicrobial Resistance of Responsible Pathogens in Ukraine: Results a Multicenter Study

Salmanov, Aidyn G; Savchenko, S.E.; Чайка, К. В.; Vitiuk, Alla D; Ruban, Iana; Dyndar, O.A.; Zhelezov, D. M.; Vorobey, L.I.; Semeniuk, Liudmula M; Hetsko, N. V.; Tsmur, Olga; Суслікова, Л.В.; Nykoniuk, T.R.; Shunko, Yelizaveta Ye; Beketova, Halyna V.; Manzhula, Lyudmila V; Kurochka, V.V.; Abbasova, Esmira R

doi:10.36740/wlek202005111

Cited by 12 publications

(24 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective analysis of strains isolated from the patients with respiratory tract infections found increasing AMR resistance of P. aeruginosa and A. baumanii [ 165 ]. A ten-year surveillance study of pathogens implicated in urinary tract infections revealed a significant increase in the proportions of multidrug-resistant bacteria and fluoroquinolone-resistant E. coli [ 166 ]. The recent studies examined the prevalence of MRSA and Methicillin-resistant Staphylococcus epidermidis (MRSE) and ESBL production among Enterobacteriaceae in postpartum mastitis [ 167 ] and postpartum endometritis [ 168 ].…”

Section: A Snapshot Of Amr Surveillance Programs and The Epidemiologymentioning

confidence: 99%

Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture

Iskandar

Molinier

Hallit

et al. 2021

Antimicrob Resist Infect Control

232

144

View full text Add to dashboard Cite

Data on comprehensive population-based surveillance of antimicrobial resistance is lacking. In low- and middle-income countries, the challenges are high due to weak laboratory capacity, poor health systems governance, lack of health information systems, and limited resources. Developing countries struggle with political and social dilemma, and bear a high health and economic burden of communicable diseases. Available data are fragmented and lack representativeness which limits their use to advice health policy makers and orientate the efficient allocation of funding and financial resources on programs to mitigate resistance. Low-quality data means soaring rates of antimicrobial resistance and the inability to track and map the spread of resistance, detect early outbreaks, and set national health policy to tackle resistance. Here, we review the barriers and limitations of conducting effective antimicrobial resistance surveillance, and we highlight multiple incremental approaches that may offer opportunities to strengthen population-based surveillance if tailored to the context of each country.

show abstract

Section: A Snapshot Of Amr Surveillance Programs and The Epidemiologymentioning

confidence: 99%

Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture

Iskandar

Molinier

Hallit

et al. 2021

Antimicrob Resist Infect Control

232

144

View full text Add to dashboard Cite

show abstract

“…Mastitis can jeopardize breastfeeding, but also the consequent use of antibiotic during the perinatal period is of great concern. Broad spectrum antibiotics are used to treat mastitis because of the increase of MRSA isolates and the increasing involvement of other bacterial species [ 29 , 30 ], a fact that might contribute to the worldwide emergence of antibiotic resistances among clinically relevant bacteria [ 31 , 32 ]. In our study, the use of antibiotics by women who suffered mastitis was not statistically different in the probiotic group (44% of women suffering mastitis) compared to the 72.7% in the placebo group ( p = 0.217).…”

Section: Discussionmentioning

confidence: 99%

Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial

et al. 2021

View full text Add to dashboard Cite

Mastitis is considered one of the main reasons for unwanted breastfeeding cessation. This study aimed to investigate the preventive effect of the probiotic strain Ligilactobacillus salivarius PS2 on the occurrence of mastitis in lactating women. In this multicountry, multicenter, randomized, double-blind, placebo-controlled trial, 328 women were assigned to the probiotic or the placebo group. The intervention started from the 35th week of pregnancy until week 12 post-partum. The primary outcome was the incidence (hazard) rate of mastitis, defined as the presence of at least two of the following symptoms: breast pain, breast erythema, breast engorgement not relieved by breastfeeding, and temperature > 38 °C. The probability of being free of mastitis during the study was higher in the probiotic than in the placebo group (p = 0.022, Kaplan–Meier log rank test) with 9 mastitis cases (6%) vs. 20 mastitis cases (14%), respectively. The hazard ratio of the incidence of mastitis between both study groups was 0.41 (0.190–0.915; p = 0.029), indicating that women in the probiotic group were 58% less likely to experience mastitis. In conclusion, supplementation of L. salivarius PS2 during late pregnancy and early lactation was safe and effective in preventing mastitis, which is one of the main barriers for continuing breastfeeding.

show abstract

“…In one study, more women with mastitis were found to have S. aureus and Group B streptococci in their milk than those mothers without symptoms (10). Notably, a growing percentage of S. aureus infections have been found to be methicillin-resistant (11,12). In addition, coagulase-negative staphylococci have also been commonly found associated with mastitis (8).…”

Section: Introductionmentioning

confidence: 99%

Breast Pumps and Mastitis in Breastfeeding Women: Clarifying the Relationship

Mitoulas

Davanzo

2022

Front. Pediatr.

View full text Add to dashboard Cite

Mastitis is a debilitating condition that can impact around 20% of mothers and is characterized by fever, flu-like symptoms and tender, swollen areas of the breasts. Despite the emerging evidence that breast milk dysbiosis is an underlying cause of mastitis, breast pumps have been implicated as a predisposing risk factor in the pathophysiology of mastitis in breastfeeding mothers. Previous studies have suggested that the use of a breast pump increases a mother's risk for developing mastitis, however, incidence rates of mastitis over the stages of lactation do not match breast pump usage rates. Furthermore, breast pumps, even when used at low vacuum, still promote some breast drainage, thus avoiding milk stasis, which is considered a key factor in the development of mastitis. As a consequence, these data suggest that the literature association of breast pumps with mastitis is more a case of reverse causation and not direct association. Moreover, it is important to note that breast pumps are actually a part of the conservative management of mastitis. In combination, these data show that the breast pump should not be considered a driver in the pathophysiology of mastitis in women.

show abstract

Postpartum Mastitis in the Breastfeeding Women and Antimicrobial Resistance of Responsible Pathogens in Ukraine: Results a Multicenter Study

Cited by 12 publications

References 26 publications

Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture

Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture

Ligilactobacillus salivarius PS2 Supplementation during Pregnancy and Lactation Prevents Mastitis: A Randomised Controlled Trial

Breast Pumps and Mastitis in Breastfeeding Women: Clarifying the Relationship

Contact Info

Product

Resources

About